Alnylam Pharmaceuticals (ALNY) Stock Rating Upgraded by Goldman Sachs Group

Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a buy rating to a conviction-buy rating in a research report report published on Friday morning, The Fly reports.

ALNY has been the subject of several other research reports. Credit Suisse Group lifted their price objective on Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the stock an outperform rating in a report on Friday, November 3rd. Needham & Company LLC reissued a buy rating and issued a $85.00 price objective (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Piper Jaffray Companies reissued an overweight rating and issued a $14.71 price objective (down previously from $188.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, November 2nd. B. Riley initiated coverage on Alnylam Pharmaceuticals in a report on Wednesday, November 1st. They issued a buy rating and a $240.00 price objective for the company. Finally, Nomura initiated coverage on Alnylam Pharmaceuticals in a report on Thursday, September 14th. They issued a reduce rating and a $56.00 price objective for the company. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $121.85.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) opened at $122.76 on Friday. Alnylam Pharmaceuticals has a 52 week low of $35.98 and a 52 week high of $147.63. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The business had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. During the same quarter in the previous year, the firm earned ($1.21) earnings per share. The company’s revenue for the quarter was up 24.8% on a year-over-year basis. analysts anticipate that Alnylam Pharmaceuticals will post -5.21 earnings per share for the current year.

In other news, CEO John Maraganore sold 74,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $126.86, for a total transaction of $9,387,640.00. Following the completion of the transaction, the chief executive officer now owns 223,710 shares of the company’s stock, valued at $28,379,850.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Barry E. Greene sold 76,815 shares of the business’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the transaction, the president now directly owns 165,399 shares of the company’s stock, valued at approximately $16,539,900. The disclosure for this sale can be found here. Insiders have sold 393,212 shares of company stock valued at $48,109,436 in the last three months. 4.30% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. State of Wisconsin Investment Board grew its holdings in shares of Alnylam Pharmaceuticals by 0.7% during the second quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock worth $1,197,000 after purchasing an additional 100 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 167 shares during the last quarter. Utah Retirement Systems lifted its position in Alnylam Pharmaceuticals by 1.5% in the 2nd quarter. Utah Retirement Systems now owns 13,800 shares of the biopharmaceutical company’s stock worth $1,100,000 after buying an additional 200 shares during the last quarter. Prudential Financial Inc. lifted its position in Alnylam Pharmaceuticals by 4.8% in the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 200 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its position in Alnylam Pharmaceuticals by 0.8% in the 2nd quarter. Alliancebernstein L.P. now owns 47,873 shares of the biopharmaceutical company’s stock worth $3,818,000 after buying an additional 398 shares during the last quarter. 88.39% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://sportsperspectives.com/2017/12/19/alnylam-pharmaceuticals-alny-stock-rating-upgraded-by-goldman-sachs-group.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

The Fly

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply